FIELD: chemistry.
SUBSTANCE: invention relates to a co-crystalline form of 1-[(5-para-methyl-meta-chloro-phenylamino)-1,2,4-thiadiazol-3-yl]propanol with oxalic acid in molar ratio of 1-[(5-para-methyl-meta-chloro-phenylamino)-1,2,4-thiadiazol-3-yl]-propanoland oxalic acid in ratio of 2:1. Has an endothermic peak from 125 to 150 °C, according to measurement using differential scanning calorimetry (DSC analysis), having peaks at angle values of 2θ(°) 6.1, 10.1, 12.3, 14.8, 15.7, 18.6, 19.4, 20.0, 20.3, 20.7, 23.6, 24.1, 26.6, 25.6 from powder X-ray powder diffraction measurement data.
EFFECT: co-crystal of 1-[(5-para-methyl-meta-chloro-phenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid, suitable for production of pharmaceutical preparations for treating various neurodegenerative diseases, including in Alzheimer's disease therapy, having high solubility.
1 cl, 2 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COCRYSTALLINE FORM OF 1-[5-(4-CHLOROPHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2018 |
|
RU2712443C1 |
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
| COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
| HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
